Adaptimmune therapeutics plc ( afami-cel ) and our first - generation afami-cel are promising cell therapies for patients with synovial sarcoma and the first allogeneic system for the treatment of platinum resistant ovarian cancer. we have made the difficult decisions to focus the company prioritizing our pipeline and reducing the headcount to extend our cash runway into early 2025. we anticipate that our cash runway will extend to early 2025 as we change [sub-lines] [ph] for our myriad of afami-cel and our second generation afami-cel product targeting synovial sarcoma and the second generation afami-cel product targeting ovarian urothelial and head and neck cancers. we will continue to make the choices necessary for Adaptimmune to successfully develop cell-therapies to transform the oncology landscape.